Chemistry:Resigratinib

Resigratinib
Identifiers
CAS Number	2750709-91-0;
PubChem CID	162381323;
Chemical and physical data
Formula	C26H27F2N7O3
Molar mass	523.545 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC1=C(C(=NN1[C@H]2C[C@@H](N(C2)C(=O)C=C)COC)C#CC3=C(C=C4C(=C3F)N=CN4C5CC5)F)C(=O)N;
	InChI InChI=1S/C26H27F2N7O3/c1-4-21(36)33-11-15(9-16(33)12-38-3)35-26(30-2)22(25(29)37)19(32-35)8-7-17-18(27)10-20-24(23(17)28)31-13-34(20)14-5-6-14/h4,10,13-16,30H,1,5-6,9,11-12H2,2-3H3,(H2,29,37)/t15-,16+/m0/s1; Key:YXVDEILMUVTDMK-JKSUJKDBSA-N;

Short description: Chemical compound

Resigratinib (KIN-3248) is an experimental anticancer medication which acts as a fibroblast growth factor receptor inhibitor (FGFRi) and is in early stage human clinical trials.^[1]^[2]^[3]

References

↑ "Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.". Journal of Clinical Oncology 40 (4_suppl): 461. February 2022. doi:10.1200/JCO.2022.40.4_suppl.461.
↑ "First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.". Journal of Clinical Oncology 41 (4_suppl): TPS637-TPS637. February 2023. doi:10.1200/JCO.2023.41.4_suppl.TPS637.
↑ "Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer". Cancer Journal (Sudbury, Mass.) 28 (5): 354–362. 2022. doi:10.1097/PPO.0000000000000615. PMID 36165723.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Resigratinib. Read more

[1] "Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.". Journal of Clinical Oncology 40 (4_suppl): 461. February 2022. doi:10.1200/JCO.2022.40.4_suppl.461.

[2] "First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.". Journal of Clinical Oncology 41 (4_suppl): TPS637-TPS637. February 2023. doi:10.1200/JCO.2023.41.4_suppl.TPS637.

[pmid36165723-3] "Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer". Cancer Journal (Sudbury, Mass.) 28 (5): 354–362. 2022. doi:10.1097/PPO.0000000000000615. PMID 36165723.

[1]

[2]

[3]

Anonymous

Search

Chemistry:Resigratinib

Namespaces

More

Page actions

See also

References

Navigation

Navigation

Help

Translate

Wiki tools

Wiki tools

Identifiers

CAS Number	2750709-91-0
PubChem CID	162381323
Chemical and physical data
Formula	C₂₆H₂₇F₂N₇O₃
Molar mass	523.545 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CNC1=C(C(=NN1[C@H]2C[C@@H](N(C2)C(=O)C=C)COC)C#CC3=C(C=C4C(=C3F)N=CN4C5CC5)F)C(=O)N
InChI InChI=1S/C26H27F2N7O3/c1-4-21(36)33-11-15(9-16(33)12-38-3)35-26(30-2)22(25(29)37)19(32-35)8-7-17-18(27)10-20-24(23(17)28)31-13-34(20)14-5-6-14/h4,10,13-16,30H,1,5-6,9,11-12H2,2-3H3,(H2,29,37)/t15-,16+/m0/s1 Key:YXVDEILMUVTDMK-JKSUJKDBSA-N

Anonymous

Search

Chemistry:Resigratinib

See also

References

Navigation

Wiki tools

Page tools

Other projects

Categories